Compare Magnolia Oil & Gas Corporation Class A Common Stock (MGY) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Magnolia Oil & Gas Corporation Class A Common Stock vs State Street SPDR S&P Biotech ETF — how do they compare? Magnolia Oil & Gas Corporation Class A Common Stock trades at $24.9 (market cap $6.76B), while State Street SPDR S&P Biotech ETF trades at $147.13 (market cap $10.27B). The key difference: State Street SPDR S&P Biotech ETF is the larger of the two by market cap, and Magnolia Oil & Gas Corporation Class A Common Stock pays a 2.63% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Magnolia Oil & Gas Corporation Class A Common Stock for 0 Days and State Street SPDR S&P Biotech ETF for 39 Days on average.
| MGY | XBI | |
|---|---|---|
Market Cap | $6.76B | $10.27B |
Volume | 2,815,157 | 9,751,587 |
Sector | Energy | Broad Market / Factor |
52-Week High | $32.36 | $169.55 |
52-Week Low | $21.24 | $107.32 |
Typical Hold Time | 0 Days | 39 Days |
Enterprise Value | $6.88B | — |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Magnolia Oil & Gas (MGY) trades at $25.11, up 2.66% with neutral technical signals. The company demonstrates strong fundamentals with a P/E of 10.97, net income margin of 28.77%, and consistent earnings beats. Recent WildFire Energy acquisition positions MGY for production doubling and significant free cash flow growth, with 2027 FCF projected over $1 billion. Analyst consensus remains strongly bullish with 66.7% buy ratings and $33.78 price target.
MGY presents compelling value with attractive valuation multiples and robust profitability metrics. The WildFire acquisition accelerates growth but introduces integration execution risk. Current price offers 35% upside to consensus target, though oil price volatility and operational execution remain key watchpoints for investors.
XBI trades at $146.8, down 3.04% today, with a bearish technical signal driven by selling pressure in moving averages. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from M&A activity and positive clinical catalysts. Recent news highlights sector optimism from cancer vaccine breakthroughs and improved capital access, though the ETF carries higher volatility than diversified healthcare funds.
Outlook remains mixed with neutral analyst consensus but positive sector catalysts. Opportunities include biotech innovation and M&A potential, while risks involve high volatility, regulatory uncertainty, and expense ratios above broader healthcare ETFs. Investors should weigh targeted biotech exposure against sector-wide stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Magnolia Oil & Gas Corporation Class A Common Stock
Magnolia Oil & Gas Corporation is an independent oil and gas exploration and production company operating in the Eagle Ford Shale and Austin Chalk formations of South Texas.
Read more on MGY →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
